Lung Cancer

The FDA granted two fast track designations to TT125-802, an investigational therapy, for the treatment of advanced/metastatic non-small cell lung cancer.

Clara Mae Cirk, a 30-year-old diagnosed with stage 4 lung cancer, shares how cancer has reshaped her perspective on strength and self-care.

Lung cancer affects up to 25% of non-smokers, so persistent symptoms and genetic testing are key for early detection and treatment.

FDA grants D3S-001 treatment breakthrough therapy for KRAS G12C some with lung cancer and orphan drug status for KRAS G12C colorectal cancer in adults.

Hideko Warner shared how she faced three cancers at once and became the first in Orange County to receive biology-guided radiation therapy with no side effects.

Clara Mae Cirk, a 30-year-old who was diagnosed with stage 4 lung cancer, opens up about her journey and using social media as an outlet to educate others.

In a defining moment for both my husband and me, we learned of the need for and the meaning of support during a cancer journey.

Through three family cancer diagnoses, and my own life-threatening stage 3b lung cancer verdict, family support and reconnection helped support me.

The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung cancer.

Dr. Jacob Sands explained that he believes patients should be having more personalized, nuanced conversations with their oncologists.

The FDA has approved the Oncomine Dx Target Test to identify patients with HER2-mutant non-small cell lung cancer who are eligible for Hernexeos treatment.

Beginning treatment for your lung cancer often brings questions surrounding what side effects will be experienced, according to Dr. Jacob Sands.

The FDA approved Hernexeos for adults with unresectable or metastatic non-squamous non-small cell lung cancer.

Following the June 2025 FDA approval of Datroway, Dr. Jacob A. Sands explained the significance of the regulatory approval for patients with lung cancer.

After joining a creative survivors’ group, I discovered that emotional expression, art and connection offered a profound kind of healing beyond treatment.

In July of 2025, the U.S. Food and Drug Administration approved various anti-cancer treatments and therapeutic approaches across a range of disease types.

LiveLung invites the Wilmington community to its monthly educational meeting.

The August LiveLung Virtual meeting will feature Nitin Ohri, MD, MS, Board Certified Radiation Oncologist and Professor of Radiation Oncology at Montefiore Einstein.

LiveLung invites the Triad lung cancer community to its monthly educational meeting.

CURE spoke with a thoracic surgeon about the impact of minimally invasive surgery for patients.

Dr. Jacob Sands discusses the significance of the FDA approval of Datroway for the treatment of patients with locally advanced or metastatic EGFR+ NSCLC.

As July concludes, momentum in lung cancer research continues to build, marked by FDA decisions, trial progress, and patient-centered perspectives.

The FDA awarded orphan drug designation to VT3989 for mesothelioma, supporting the experimental cancer treatment’s development.

Dr. Jacob Sands discusses progress in lung cancer treatment, as well as what patients should understand about how their care options may evolve over time.